These results are consistent with the known/suspected mechanism of action of anti-PD-L1 and anti-PD-1 therapies, which are thought to enhance productive neoantigen presentation to T cells, leading to T-cell attack and tumour shrinkage.45 This evidence concerns the gene CD274 and neoplasm.